Both Methanol and Water Mixture Extracts of Panax Notoginseng Flower Affect Platelet Function and Thrombus Growth by Down-Regulating PI3K/AKT and MAPKs Signaling Pathways

Xiao Zuo  
School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, Guangdong Province 510080

Nan Qin  
Department of Clinical laboratory, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province 510260

Yu-Heng Mao  
School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, Guangdong Province 510080

Lijuan Ma  
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao, 999078

Qing Li  
Department of Food and Nutrition Sciences, Life Science, MMW505, The Chinese University of Hong Kong, Shatin, N.T.

Zezhong Tian  
School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, Guangdong Province 510080

Mingzhu Zhao  
School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, Guangdong Province 510080

Qiuhua Ji  
School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, Guangdong Province 510080

Yiting Chen  
School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, Guangdong Province 510080

Jian-Bo Wan  
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao, 999078

Yan Yang (yangyan3@mail.sysu.edu.cn)  
School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, Guangdong Province 510080

Research Article

Keywords: Chinese herbal medicine, Ginseng, platelets, saponins, thrombosis
Abstract

**Background:** Platelet dysfunction plays a central role in the pathogenesis of cardiovascular diseases (CVDs). We previously found that two sapon monomers isolated from *Panax notoginseng* flowers (PNF) have shown to exhibit anti-platelet activity, and here we used methanol and water extraction methods to gain two mix extracts of PNF (PNFM and PNFW) and further investigated the effects and the underlying mechanisms of PNFM and PNFW on platelet functions and thrombosis.

**Methods:** Healthy human PRP or gel-filtered platelets were collected for *in vitro* assay the PNFM and PNFW on the function and activation of platelets, while FeCl3-injured thrombosis formation in mice mesenteric arteriole was applied for *in vivo* assessment. Western blot analysis was applied to study the mechanic pathways.

**Results:** The results showed that both PNFM and PNFW significantly inhibited human platelet aggregation and activation stimulated with either ADP or thrombin with a dose-effect relationship, and inhibited platelet granule-secretion and spreading *in vitro*. Furthermore, PNFM and PNFW attenuated thrombus formation in mice. The effects might be associated with inhibition of platelet PI3K, Akt, P38, JNK and Erk phosphorylation.

**Conclusion:** These findings suggest that PNF mixture extracts could be developed as a functional ingredient to improve cardiovascular health through inhibiting platelet hyper reaction.

1. **Introduction**

Cardiovascular diseases (CVDs), including atherosclerosis and thromboembolic diseases, have become the leading causes of disease burden and death globally (G. B. D. Risk Factors Collaborators, 2017; G. B. D. Risk Factor Collaborators, 2018; 2018). Platelets, the small versatile anucleate cells, play a central role in both the progression of atherosclerotic plaques and thrombus formation (X. R. Xu et al., 2016). Excessive platelet activation, granule release, and aggregation are key events during thrombogenesis (Jagadeeswaran, Cooley, Gross, & Mackman, 2016). Platelet activation is mediated by a variety of extracellular stimuli such as thrombinandadenosine 5'-diphosphate (ADP), which bind to G-protein coupled receptors thus leading to subsequent activation of intracellular downstream signaling molecules (Kunapuli et al., 2003). Phosphoinositide 3-kinase (PI3K) pathway and the mitogen-activated protein kinases (MAPK) pathway are two common pathways contributing to platelet activation (Z. Li, Delaney, O'Brien, & Du, 2010).

Due to the critical role of platelet in thrombus formation, antiplatelet therapy has become a useful strategy to prevent acute thromboembolic artery occlusions in cardiovascular diseases (Schror, 1995; Sharma & Berger, 2011). However, most of the antiplatelet agents may lead to severe adverse effects, especially under a high dosage or a long course of treatment. The increasing bleeding risk limited the clinical applications of many antiplatelet medicines (Michelson, 2010). Therefore, the development of novel natural antiplatelet agents without bleeding risk have been attracted the increasing attention.
Panax notoginseng, a well-known and valuable Chinese medicine, has been widely used for the treatment of CVD more than 400 years (L. Wang et al., 2013). Among the different parts of the plant, P. notoginseng flowers (PNF) contain the highest abundance of saponins. A numerous studies indicated that PNF exert the beneficial effects on hypertension, insomnia, and stomatitis. Our previous study reported that two monomers (G-Rb2 and G-Rd2) from PNF significantly inhibited human platelet aggregation and activation induced by adenosine diphosphate (ADP) in vitro. However, the effects of PNF mixture extracts on platelet function were unclear yet.

Methanol and water are the two most common solvents to extract the bioactive compounds of herbal medicine. Our previous studies have demonstrated that ginsenoside profiles of PNF (Ma, Liu, Zhong, & Wan, 2017) or P. notoginseng leaves (Sun, Ma, Wan, & Tong, 2021) extracted by methanol and water were remarkably different, and the difference between the two extracts may due to the ginsenoside transformations happened during the water extraction process. Specifically, we found that ginsenoside Rb1 (G-Rb1, 1), G-Rc (2), G-Rb2 (4), G-Rb3 (5) and G-Rd (5), the major saponins of PNF, can be largely converted into gypenoside XVII (GY-XVII, 6), notoginsenoside Fe (NG-Fe, 7), G-Rd2 (8) and NG-Fd (9) and G-F2 (10), respectively, through selectively cleaving the β- (1→2) - glucosidic linkage at the C-3 site of ginsenosides without hydrolyzing other glycosidic linkages (Ma, Ma, Cao, & Wan, 2022). It was proposed that PNF extracted by methanol (PNFM) and water (PNFW) may exert different healthy effects due to their different components (Ma et al., 2017). The aim of the present study, therefore, was to investigate the effects of two mixture extracts PNFM and PNFW on human platelet functions and the underlying mechanisms.

2. Materials And Methods

2.1 Chemicals and antibodies

Chemical reference standards, including G-Rb1 (1) and NG-Fe (8), were supplied by National Institute for the Control of Pharmaceutical and Biological Products (Beijing, PR China). G-Rc (2), G-Rb2 (4), and G-Rb3 (5) were purchased from Must Bio-technology (Chengdu, PR China). NG-Fc (3), NG-Fd (10), G-Rd2 (9), and GY-XVII (7) were supplied by Baoji Herbest Bio-Tech (Baoji, PR China). The purity of each reference standard was over 98 % measured by HPLC–UV. LC-grade acetonitrile and methanol were purchased from Merk (Darmstadt, Germany). ADP and thrombin were purchased from Sigma-Aldrich (St. Louis, MO, USA). Antibodies for FITC-conjugated anti-human CD62P, PAC-1 and IgG1 isotype control were purchased from BD Biosciences (San Jose, CA, USA). Alexa FluorTM 488-Conjugated anti-human fibrinogen antibody was purchased from Thermo Fisher Scientific (Waltham, MA, USA). Antibodies for β-actin, phospho-Akt (Ser473), phosphor-PI3k (Tyr458), phospho-p38 (Thr180/Tyr182), phospho-ERK1/2 (Thr202/Tyr204), and phospho-JNK (Thr183/Tyr185) were purchased from Cell Signaling Technology (Beverly, MA, USA). The ultra-pure water (18.2 MΩ.cm at 25°C) was purified by a Milli-Q purification system (Millipore, Bedford, MA, USA).

2.2 Preparation of PNF extracts and Chemical analysis
PNF was purchased from a drug store in Kunming, Yunnan Province, China. Their botanical origin of materials was authenticated by Professor Ni Ma from WenshanSanqi Institute of Science and Technology, Yunnan, China. The preparation of PNFM and PNFW was performed as described previously with slight modification (Ma et al., 2017). Approximate 36 g of PNF fine powder was ultrasonically (135 W) extracted by 360 mL of methanol or water for 2 h in an ultrasonic bath (40 kHz, Bransonic, USA). After filtration, the extracts were concentrated under the reduced pressure in a rotary vacuum evaporator at 50°C followed by lyophilization. The freeze-dried extracts were reconstituted in distilled water for the following in vivo study.

The chromatographic analysis was performed on an Agilent 1290 Infinity II UPLC system (Agilent Technologies, Santa Clara, CA, USA), equipped with an Agilent 1290 DAD. The separation was achieved on a Kinetex C18 column (100 mm × 4.6 mm, 2.6 μm, Phenomenex). The mobile phases were consisted of water (A) and acetonitrile (B) at a flow rate of 0.6 mL/min. The linear gradient program was adopted as follows: 0-5 min, 34% B; 5-6 min, 36-38.5% B; 6-12 min, 38.5-45% B; 12-12.5 min, 34% B. The detection wavelength was set at 203 nm and the column temperature was kept at 40°C. Each sample was filtered through a 0.22 μm membrane before the injection. The injection volume was 2 μL.

2.3 Human blood preparation

Healthy male and female volunteers aged between 25 to 40 years who had not taken any antiplatelet drugs within the previous 2 weeks were recruited for this study. Written informed consents were obtained from all subjects. This study was approved by the Ethics Committee of School of Public Health, Sun Yat-sen University [(2019) No. 134]. The anticoagulated whole human blood was collected to prepare platelet-rich plasma (PRP) and gel-filtered platelets as our previously described (Song et al., 2014; Ya et al., 2019; Yao et al., 2017).

2.4 Lactate dehydrogenase activity determination

To evaluate the platelet cytotoxicity, the leakage of lactate dehydrogenase (LDH) was determined by LDH assay kit (Beyotime Institute of Biotechnology, Jiangsu, China) according to the manufacturer's instruction. Gel-filtered platelets (1 × 10^8 platelets/mL) were pre-incubated with PNFM or PNFW (0 - 2000 μg/mL) for 20 min, and then centrifuged at 3000 rpm for 5 min at room temperature. LDH released was expressed as percentage (%) compared with the positive control (0.1 % triton) lysed by LDH release reagent treatment.

2.5 Assay of platelet aggregation

Human PRP or gel-filtered platelets were incubated with PNFM or PNFW at different concentrations (100, 300, and 500 μg/mL) or the control buffer for 20 min at 37°C according to previous study (Zuo et al., 2021). Platelet aggregation was induced at 37°C with a sample stir speed of 1000 rpm in an aggregometry (Chrono-Log, Havertown, PA) using ADP (5 and 10 μM) or thrombin (0.5 U) as the agonists. Aggregation was recorded for 6 min as our previously described methods (Song et al., 2014).
2.6 Flow cytometry analysis of CD62P expression, PAC-1 binding and fibrinogen binding to activated platelets

PRP and gel-filtered platelets were incubated with different concentrations of PNFM, PNFW or the control buffer at 37°C for 20 min. Aliquots of sample (5×10^5 platelets) were incubated with FITC-conjugated anti-human CD62P and PAC-1 antibodies, Alexa FluorTM 488-Conjugated anti-human fibrinogen binding antibody or FITC-conjugated anti-human IgG1 antibody (isotype control), respectively, at room temperature for 30 min. PRP were activated with 200 µM ADP for 5 min while gel-filtered platelets with 0.5 U/mL thrombin in the presence of 1mM Ca^{2+} for 5 min. The platelets were fixed with 1% paraformaldehyde before flow cytometry analysis.

2.7 Platelet ATP release assay

The secretion of ATP was determined in a Chrono-log lumiaggregometer according to the manufacturer’s instructions. Briefly, PRP at 2.5×10^8 platelets/mL were incubated with different concentrations of PNFM, PNFW and the control buffer at 37°C for 20 min as described above. Luciferin-luciferase reagent was added directly to platelet suspensions, which were continually stirred at 1,000 rpm at 37 °C. 5 µM or 10 µM ADP was added to activate platelets and real-time ATP secretion was monitored.

2.8 Assay of soluble β-thromboglobulin (β-TG)

To detect platelet β-TG in vitro, PRP (2.5×10^8 platelets/mL) was pre-incubated with different concentrations of PNFM, PNFW or control buffer for 20 min at 37°C as described, and then stimulated with 5 µM ADP, followed by centrifugation at 10000 × g for 5 min at 4°C. The cell-free supernatant was collected by a new clean tube and stored at -80°C until use. β-TG levels in supernatant were determined using a β-TG ELISA kit (BlueGene Biotech, Shanghai, China) according to the manufacturer’s instruction.

2.9 Assay of platelet Ca^{2+} mobilization

The intracellular calcium ion concentration was measured using Fluo-3AM as a calcium ion fluorescence probe. Briefly, PRP (2.5 × 10^8 platelets/mL) was incubated with 10 µM Fluo-3AM for 30 min at 37°C. The Fluo-3-loaded platelets were pre-incubated with different concentrations of PNFM or PNFW for 20 min at 37°C in the presence of 1mM CaCl_2, and then stimulated with 200 µM ADP or 0.5 U thrombin. Fura-3 fluorescence in the cytosol was measured by a spectrofluorometer as the following formula: [Ca^{2+}]_i (nM) = 224×(F-F_{min})/(F_{max}-F), where 224 is the dissociation constant of the Fura-3-Ca^{2+}complex, and F_{min} and F_{max} are the fluorescence intensities at very low and very high Ca^{2+} concentrations, respectively.

2.10 Platelet spreading on immobilized Fibrinogen

Chamber slides with microtiter wells were coated with 100 µg/mL fibrinogen overnight at 4°C. PRP were incubated with different concentrations of PNFM, PNFW and the control buffer for 20 min at 37°C as described above. The platelets were allowed to adhere and spread on fibrinogen-coated wells at 37°C for
1 h. After washing, the cells were fixed, permeabilized, and stained with Alexa Fluor 488-conjugated phalloidin before observing with an inverted fluorescence microscope. The spreading areas of single platelet were measured using ImageJ software. Ten randomly selected fields from at least three parallel tests were used for statistical analysis.

2.11 Western blot analysis

After incubation with PNFM, PNFW and the control buffer for 20 min, platelets were activated with ADP (5 μM) or Thrombin (0.5 U) in the presence of 1 mM Ca^{2+} for 5 min. Platelet were harvested and lysed with RIPA buffer supplemented with protease and phosphatase inhibitors for 30 min on ice. After centrifugation at 12000 g for 15 min. the supernatants were collected as platelet total protein for western blot analysis. The protein concentrations were determined using a commercial BCA kit (Thermo Fisher Scientific, Rockford, IL). Equal amounts of protein (20 - 50 μg) were fractionized on 10% SDS-PAGE gels and transferred onto a polyvinylidene difluoride (PVDF) membrane. The membranes were blocked with 5% nonfat milk in TBST and then incubated with each primary antibodies including β-actin, GAPDH, phospho-PI3K, phospho-Akt, phospho-Erk1/2, phospho-JNK, phospho-p38 and corresponding secondary antibodies. The target proteins were detected with an enhanced chemiluminescence (ECL) reagent (Thermo Scientific, Waltham, MA, USA) in an automatic chemiluminescence image analysis system.

2.12 Assay of FeCl_{3}-injured thrombosis formation in mice mesenteric arteriole

Intravital microscopy of FeCl_{3}-induced thrombus formation in 3 to 4-week male C57BL/6J mice mesenteric arteriole was performed as described previously (Zuo et al., 2021). The animal experiments were approved by the Animal Care and Use Committee of Sun237 Yat-sen University (No. SYXK [Yue] 2017-0080). Briefly, after injection of PNFM, PNFW (30 μg/g BW), or control buffer via the tail vein followed by inject calcein-labeled (4 μg/mL) mice platelets. The dose of PNFM and PNFW in animal experiments was calculated according to the dose of in vitro experiments, approximately 500 μg/mL as the final concentration in the murine blood. The injury was induced by topical application of FeCl_{3}. Images of thrombus formation and dissolution were visualized by a fluorescence microscope (Leica Microsystems, Wetzlar, Hesse, Germany). Based on the time to complete the vessel occlusion, the images from each group are compared with those from the other groups.

2.13 Assay of bleeding time in mice

Male C57BL/6J mice (6-8 weeks old) were injected with PNFM, PNFW (30μg/g BW) or the control buffer via the tail vein 20 min before the bleeding time assay. Mice were then anesthetized with sodium pentobarbital and maintained at 37°C on a heating pad during the experiment. The 5 mm tip of tail was cut off and placed into 37°C saline solutions immediately. The bleeding time was calculated from the moment blood began emerging to the moment bleeding ceased.

2.14 Statistical analysis
GraphPad Prism version 5.01 software (GraphPad Inc., San Diego, CA, USA) was used for statistical analyses. Data are expressed as the means ± standard deviation (SD) of at least three independent experiments. The statistical significance among different groups was determined using one-way ANOVA. Differences were considered significant at $P < 0.05$.

3. Results

3.1 Chromatographic analysis of major ingredients

The contents of abundant saponins, G-Rb1, G-Fc, G-Rc, G-Rb2, G-Rb3, GY- XVII, NG-Fe, G-Rd2 and NG-Fd in water extracts and methanol extracts of PNF were determined by an optimized UPLC-UV chromatographic condition. The saponins in different PNF extracts were well separated (Fig. 1). As shown in Fig. 1, the UPLC profiles of PNFM and PNFW were remarkably different. The G-Rb1 (1), G-Fc (2), G-Rc (3), G-Rb2 (4), and G-Rb3 (5) were found as the major saponins in PNFM. Compared to PNFM, the contents of G-Rb1 (1), G-Rc (3), G-Rb2 (4), and G-Rb3 (5) were decreased and the contents of GY-XVII(6), NG-Fe(7), G-Rd2(8) and NG-Fd(9) were greatly increased after water immersion. These findings suggested that ginsenoside transformations happen upon the extraction with water.

3.2 PNFM and PNFW inhibit human platelet aggregation in vitro

Both PNFM and PNFW significantly inhibited ADP- and thrombin-induced human platelet aggregation in a dose-dependent manner (Fig. 2A-C). Additionally, PNFW at 300 μg/mL exhibited a more potent effect on the suppression platelet aggregation induced by ADP at both 5 μM and 10 μM, compared with PNFM at the same dose (Fig. 2A-B). The dosages of PNFM and PNFW used in this study had no cytotoxicity on human platelets as demonstrated by the LDH leakage assay (Supplementary Figure 1).

3.3 PNFM and PNFW attenuate human platelet surface CD62P expression, PAC-1 binding, and platelet binding to fibrinogen in vitro

CD62P expressed on platelet surface is a marker of platelet activation. Upon agonist stimulation, the transduction of intraplatelet signals leads PAC-1 to switch from a low-affinity to high-affinity state for fibrinogen, which initiates and amplifies platelet aggregation and thrombus consolidation (Ya et al., 2018). As shown in Fig. 3, both PNFM and PNFW dose-dependently inhibited ADP- and thrombin-induced CD62P expression, PAC-1 activation, and fibrinogen binding. We found the inhibitory effects of PNFW on human platelet CD62P expression were stronger comparing with PNFM at low concentration (100 μg/mL). On the contrary, the PNFM showed more potent inhibition on PAC-1 activation at all concentrations compared with PNFW. Additionally, the inhibitory effects of PNFM on thrombin-induced PAC-1 activation and fibrinogen binding were significantly stronger compared with PNFW at relatively higher concentrations (300 or 500 μg/mL).

3.4 PNFM and PNFW inhibit human platelet ATP release, β-TG expression, and Ca$^{2+}$ mobilization in vitro
Granule secretion is an important marker of platelet activation prior to aggregation and thrombus formation. As shown in Fig. 4A-C, both PNFM and PNFW decreased intraplatelet ATP release induced by ADP (5 μM and 10 μM) and thrombin (0.1 U) in a dose-dependent manner. Both PNFM and PNFW also dose-dependently reduced the intraplatelet Ca\(^{2+}\) mobilization induce by ADP and thrombin (Fig. 4D-E). Additionally, the release of intraplatelet β-TG were attenuated by PNFM and PNFW at the dose of 500 μg/mL (Fig. 4F).

3.5 PNFM and PNFW decrease human platelet spreading on immobilized fibrinogen in vitro

After fibrinogen binding to platelet PAC-1, it transduces outside-in signals into the cell and triggers platelet spreading. We next investigated whether PNFM and PNFW influence platelet spreading on immobilized fibrinogen. As shown in Fig. 4G, PNFM and PNFW substantially decreased the surface area of the spreading platelets on immobilized fibrinogen. Additionally, the inhibitory effects of PNFM on platelet spreading were more potent than those of PNFW at relatively lower dose (100 μg/mL) rather than other two higher doses.

3.6 Effects of PNFM and PNFW on phosphorylation of PI3k/Akt and MAPKs in platelets

PI3k/Akt and MAPKs (ERK, JNK, and p38 MAPK) pathways play a crucial role in platelet activation. Our results demonstrated that both PNFM and PNFW markedly down-regulated the phosphorylation of PI3k, Akt, JNK, ERK, and p38 MAPK in ADP- and thrombin-treated human platelets in a dose-dependent manner (Fig. 5). These results suggested that the ameliorative effects of PNFM and PNFW on platelet hyperactivity were possibly mediated by concomitant inhibition of PI3k/Akt and MAPK signaling pathways.

3.7 PNFM and PNFW inhibit FeCl\(_3\)-induced mesenteric thrombus formation in mice

The results of in vivo thrombus model experiment showed that 500 μg/mL of PNFM and PNFW effectively suppressed FeCl\(_3\)-induced mesenteric thrombus formation as demonstrated by the prolonged vessel occlusion time (Fig. 6A-6B). We also found that PNFW exerted more potent inhibitory effects on thrombus formation than PNFM treatment. Additionally, we found that compared with the control, the treatment of either PNFM or PNFW at 500 μg/mL had no significant influence on the tail bleeding time, which is an indicator of normal hemostasis and coagulation functions (Fig. 6C).

4. Discussion

Resting platelets circulate in the form of small discs without interacting with each other or the vascular endothelium (Blache, 1992). Upon vascular injury, platelets adhere to the subendothelial matrix becoming activated and aggregated (Z. Li et al., 2010). Platelets could be activated by various extracellular stimuli, including ADP and thrombin. ADP activates platelets mainly via the P2Y\(_1\) and P2Y\(_{12}\) receptors through positive feedback loops that amplify platelet activation (Hollopeter et al., 2001). Thrombin is regarded as the most powerful physiological platelet agonist. Thrombin could activate human platelets via a dual
system of G-protein coupled protease-activated receptors (PAR), namely PAR1 and PAR4, which promote platelet shape change, aggregation, mobilization of P-selectin to platelet surface, integrin αIIbβ3 activation and granule secretion (Angiolillo, Capodanno, & Goto, 2010). The present study showed that PNFM and PNFW effectively inhibited human platelet aggregation induced by both ADP and thrombin. Since ADP and thrombin have different receptors, we speculated that PNFM and PNFW have more comprehensive effects on platelets via various pathways, instead of working as a single specific antagonist to inhibit the binding to platelet membrane receptors.

Although the antithrombotic benefits of *P. notoginseng* roots have been well documented before (Fu et al., 2021), few studies have evaluated the medicinal use of PNF for the prevention and treatment of cardiovascular diseases. Our previous studies showed that two saponin monomers (Rb2 and Rd2) in PNF significantly attenuated platelet function (Zuo et al., 2021). In the present study, we demonstrated that both the methanol (PNFM) or water aqueous (PNFW) mixture extracts from PNF can also effectively inhibited human ADP- and thrombin-induced platelet activation, granule secretion, aggregation and platelet spreading on fibrinogen *in vitro*. Compared with the saponin monomers that are suitable for pharmaceutical application, PNF mixture extracts are more available and convenient to be utilized as a nutritional ingredient in functional food.

The pharmacological activities may differ among different ginsenosides. Our previous study has identified different ginsenoside profiles between PNFM and PNFW. The chromatographic analysis revealed that the compositional ratio of original types saponins in PNFM were obviously higher than PNFW, while the transformed types saponins were higher in PNFW than PNFM. Specifically, during the water extraction process, the β - (1→2) - glucosidic linkage at the C-3 site of ginsenosidesis selectively cleaved while other glycosidic linkage keeps intact. The major saponins in PNF methanol mixture extract ([Fig. 1A](#)), ginsenoside Rb1 (G-Rb1), G-Rc, G-Rb2, G-Rb3, and G-Rd were partially converted into other saponins, including gypenoside XVII (GY-XVII), notoginsenoside Fe (NG-Fe), G-Rd2 and NG-Fd and G-F2 ([Fig. 1B](#)) (Ma et al., 2017). In this study, although both PNFM and PNFW exerted significant effects on human platelet functions with similar dose-dependent trends, minor differences were found among different doses. The inhibitory effects of PNFW on human platelet aggregation, CD62p expression, platelet spreading and ATP release and thrombus formation were more potent than PNFM, while the effects of PNFM on αIIbβ3 activation, fibrinogen binding, and Ca$^{2+}$ mobilization were stronger than PNFW. The difference in the antithrombotic effects of PNFM and PNFW could be partially attributed to the different saponin profiles. Another study also reported that the water and methanol extracts of a traditional medicine (*Ocimum americanum*) displayed different healthy effect (Zengin et al., 2019). But the specific mechanism remained to be further studied.

Notoginsenoside Fc (NG-Fc), a main composition of both PNFM and PNFW, has been shown to inhibit platelet aggregation induced by ADP, thrombin, and collagen at submaximal concentrations (Liu et al., 2018). Except NG-Fc, among the 10 saponins isolated from PNF extracts in our previous studies have indicated that, only G-Rb2, and G-Rd2 could inhibit ADP-induced platelet aggregation at the concentration of 100 μg/mL (Zuo et al., 2021). Additionally, in the present study, our results showed that PNFM and
PNFW may have stronger antiplatelet effect than saponin monomers, as they were still effective with higher doses of agonists (10 μM ADP and 0.5 U thrombin). Notably, according to the quantitative determination of the saponins in the PNFM and PNFW (Figure 1), the effective dosage of the NG-Fc, G-Rb2, and G-Rd2 in our previous study (Zuo et al., 2021) are much higher than those saponin monomers in PNFM and PNFW. This may due to the synergistic effects of various saponin monomers in two PNF extracts, which is also consistent to a reported study that ginsenosideRp3 synergistically inhibits platelet aggregation with other ginsenosides (Irfan et al., 2018). Additionally, some other saponins with lower concentrations in PNFM and PNFW should be taken into consideration in future studies. It indicated that PNF mixture extracts at a lower dosage could confer the similar therapy compared to the saponin monomers.

Bioavailability and pharmacokinetics are two major issues influencing the health effects of natural compounds used as dietary supplements. A previous study indicated that NG-Fc have a slow elimination from plasma with a long t\(_{1/2}\) (approximately 22-30 h) and its oral bioavailability was 0.10-0.14% (He et al., 2015). Moreover, it was reported that the oral bioavailability of Rb1 was 4.35% after administering PNS to rats and the maximal concentration of plasma G-Rb1 could be reached about 50 μM after 5 min of intravenous dosing 5 μmol/kg body weight of G-Rb1 in rats (Q. F. Xu, Fang, & Chen, 2003). Additionally, it is estimated that the serum concentration of PNS after administrating Xueshuantong® Injection (a clinical medicine in which PNS is the main component) is compatible to the concentration of 100μg/mL used in this study (R. L. Li et al., 2020). Although the systemic bioavailability of PNFM and PNFW are not clearly, health effects were observed in animal studies. Orally administration of 120 mg/kg/day PNF extractions for 9 weeks significantly improved the ventricular hypertrophy state in mice (Y. Wang et al., 2012). In a myocardial infarction rats model, oral 1000 mg/kg P. notoginseng flower decoction could relieve symptoms of MI (Zhou, Li, Chen, & Xie, 2019). Although whether orally administration of PNFM and PNFW can modify platelet function and attenuate thrombus formation is unclear yet, we demonstrated platelet inhibitory effects of PNFM and PNFW in vitro in the present study, and the bioavailability and pharmacokinetics of PNFM and PNFW and their potential health benefits in vivo will be clarified in the further studies based on the present results.

PI3K/Akt and the MAPK pathways play an important role in human platelet activation and are reported in many studies (Ma et al., 2017). The inhibition of PI3K/Akt could prevent integrin αIIbβ3-mediated platelet adhesion and thrombus formation (Morello, Perino, & Hirsch, 2009). MAPKs, including JNK1, ERK2, and p38, have been identified to be involved in platelet activation induced by various agonists (Bugaud, Nadal-Wollbold, Levy-Toledano, Rosa, & Bryckaert, 1999). In the present study, we found that PNFM and PNFW significantly suppressed the activation of PI3K, Akt, and MAPKs induced by both ADP and thrombin in a dose-dependent manner. Therefore, we concluded that the inhibitory effects of PNFM and PNFW on platelet hyperactivity may partly result from concomitant inhibition of PI3K/Akt and MAPK signaling. Our results were consistent with previous study of PNF saponin monomers. G-Rb2 and G-Rd2 work on platelets by modulating P2Y12-mediated signaling in a way of up-regulating cAMP/PKA signaling and down-regulating PI3K/Akt/Erk1/2 signaling pathways (Zuo et al., 2021).
Conclusion

In conclusion, both PNF water and methanal mixture extracts inhibited ADP- and thrombin- induced platelet aggregation, activation, granule secretion and spreading without causing bleeding risk. Their inhibitory effects on platelet function might be associated with suppressing phosphorylation of PI3K/Akt and MAPKs. Compared with saponin monomers, the PNF mixture extracts are more accessible and easily produced. As natural plant extracts, they would be more acceptable by patients compared with traditional medicines. Therefore, our findings suggest that the PNF mixture extracts are valuable ingredients for application in pharmacal industry in the future and could be potentially applied in preventing thrombotic and cardiovascular diseases in the future.

Abbreviations

PNF: *Panax notoginseng* flowers; PNFM: PNF extracted by methanol; PNFW: PNF extracted by water; HPLC: high performance liquid chromatography;

Declarations

- Ethical Approval and Consent to participate

In this study, all experiments were conducted in compliance with Chinese laws or guidelines and approved by the Ethics Committee of Sun Yat-sen University. The *in vitro* experiments involving healthy donors were performed in accordance with the Declaration of Helsinki guidelines, and approved by the Ethics Committee of Sun Yat-sen University [(2019) No. 134]. Singed informed consents were obtained from human participants of this study. The *in vivo* experiments were approved by the Animal Care and Use Committee of Sun 237 Yat-sen University (No. SYXK [Yue] 2017-0080).

- Consent for publication

Not applicable.

- Availability of supporting data

Not applicable.

- Competing interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Funding

This work was supported by the grants from National Natural Science Foundation of China (No82030098 and No. 81872617), the Sun Yat-sen University Student Innovation Training Program, the Research Committee of the University of Macau (MYRG2017-00035-ICMS), the Science and Technology Development Fund, Macau SAR (File no. 034/2019/A1), and the China Postdoctoral Science Foundation (Program No. 2020T130145ZX and Program No. 2020M673025).

- Authors' contributions


- Acknowledgements

We thank all the participants in this study.

References


**Figures**

**Figure 1**

The UPLC-UV profiles of (A) PNFM, and (B) PNFW. 1, Ginsenoside Rb1; 2, Ginsenoside Fc; 3, GinsenosideRc; 4, Ginsenoside Rb2; 5, Ginsenoside Rb3; 6, GY- XVII; 7, notoginsenoside Fe; 8, Ginsenoside Rd2; 9, notoginsenosideFd.
Figure 2

Effects of PNFM and PNFW on human platelet aggregation induced by ADP and thrombin. Human platelet-rich plasma (PRP) or gel-filtered platelets were pre-incubated with control buffer or the indicated doses (100, 300, and 500 µg/mL) of *P. notoginseng* flowers extracted by methanol (PNFM) and water (PNFW) for 20 min at 37°C. A total of 250 mL of each sample was added to an aggregation cuvette and incubated for 1 min. Aggregation was induced by 5 µM and 10 µM of adenosine 5′-diphosphate (ADP) or 0.5 U thrombin and data were expressed as a percentage of maximum aggregation. Values are mean ± SD, n = 4. *p < 0.05, **p < 0.01 and ***p < 0.001, as compared to control buffer.
**Figure 3**

**Effects of PNFM and PNFW on human platelet activation.** Human platelet-rich plasma (PRP) or gel-filtered platelets were pre-incubated with control buffer or indicated doses (100, 300, and 500 μg/mL) of PNFM or PNFW for 20 min at 37°C. Effects of PNFM and PNFW on CD62P expression, αIIbβ3 activation and fibrinogen binding were measured by flow cytometry analysis. Values are mean ± SD, n = 4. *p< 0.05, **p< 0.01 and ***p< 0.001, as compared to control buffer.

**Figure 4**

**Effects of PNFM and PNFW on human platelet ATP release, β-TG expression, Ca2+ mobilization and platelet spreading on immobilized fibrinogen.** Human PRP or gel-filtered platelets were pre-incubated with control buffer or the indicated doses (100, 300, and 500 μg/mL) of PNFM and PNFW for 40 min at 37°C. 

(A-C) Adenosine triphosphate (ATP) release induced by 5μM or 10 μM ADP and 0.1U thrombin; (D-E) Effects of PNFM and PNFW on human platelet Ca^{2+} mobilization. (F) Effects of PNFM and PNFW on human platelet β-thrombomodulin (β-TG) expression induced by 5μM ADP. (G) Effects of PNFM and PNFW on human platelet spreading. The platelets were allowed to adhere and spread on fibrinogen-coated wells at 37°C for 1h, and adherent platelets were observed with an inverted fluorescence microscope. Values are mean ± SD, n = 4. *p< 0.05, **p< 0.01 and ***p< 0.001, as compared to control buffer.

**Figure 5**

**Effects of PNFM and PNFW on platelet PI3k Akt and P38 MAPK phosphorylation.** PRP or gel-filtered platelets were initially treated with indicated doses of PNFM, PNFW or vehicle, followed by activation with 5 μM ADP or 0.5 U thrombin. Platelet were collected and the cell lysates were analyzed for PI3k Akt and P38 MAPK, Erk and JNK activation. Data are presented as mean± SD. **p< 0.01 and ***p< 0.001, as compared to the ADP or thrombin control group.

**Figure 6**

**Effects of PNFM, PNFW on thrombosis formation and bleeding time.** (A-B) Thrombus formation was initiated by topical application of FeCl₃ on mesenteric arterioles in C57BL/6 male mice, which were
injected with fluorescent-labeled platelets and different extracts or control buffer. Thrombus formation was compared between groups based on the time to complete vessel occlusion. Values are mean ± SD, n = 10. ***p < 0.001, as compared to control. (C) Tail-vein bleeding times were examined in C57BL/6 mice. Either control buffer or PNFM/PNFW were administered via the tail vein 20 min before the bleeding time was determined. Values are mean ± SD, n = 8.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementarydata.docx